CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 27.86×, higher than 95% of its Biotechnology peers (median 5.64×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
727.24MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.0750xvs all stocks
52-Week Change
800.74%vs all stocks
Market Capitalization
727.24MUSDvs all stocks (USD)
Enterprise Value
685.12MUSDvs all stocks (USD)
Forward P/E
-12.36xvs Biotechnology peers
Price to Book (MRQ)
4.47xvs Biotechnology peers
Enterprise to EBITDA
-10.15xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-21.27%vs Biotechnology peers
Return on Equity (TTM)
-30.92%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-52.79MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-53.30MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-34.66MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-67.88MUSDvs all stocks (USD)
Pre-tax Income
-59.85MUSDFY2025 · Dec 31, 2025Net Income
-59.85MUSDFY2025 · Dec 31, 2025EBIT
-67.88MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-67.50MUSDFY2025 · Dec 31, 2025Research & Development
46.71MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
21.17MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
8.32MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.8800USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.8800USDFY2025 · Dec 31, 2025Basic Shares Outstanding
47.77MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
47.77MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-59.85MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-51.66MUSDFY2025 · Dec 31, 2025Free Cash Flow
-51.84MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
35.69MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-59.85MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
97.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
8.05MUSDFY2025 · Dec 31, 2025Other Non-cash Items
201.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
1.56MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.72MUSDFY2025 · Dec 31, 2025Capital Expenditures
-186.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-108.08MUSDFY2025 · Dec 31, 2025Sale of Investments
111.10MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
2.83MUSDFY2025 · Dec 31, 2025Other Financing Charges
-86.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-86.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
47.77MSharesUpdated Jul 18, 2026Float Shares
41.43MSharesUpdated Jul 18, 2026Shares Short
5.10MSharesUpdated Jul 18, 2026Short Ratio
3.10daysvs all stocks
Short % of Shares Outstanding
12.57%vs all stocks
% Held by Insiders
0.37%vs all stocks
% Held by Institutions
64.56%vs all stocks
Total Cash (MRQ)
109.56MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.91USDUpdated Jul 18, 2026Total Debt (MRQ)
479.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0032xvs Biotechnology peers
Current Ratio (MRQ)
27.86xvs Biotechnology peers
Book Value per Share (MRQ)
3.10USDUpdated Jul 18, 2026Total Assets
167.74MUSDvs all stocks (USD)
Total Current Assets
105.85MUSDFY2025 · Dec 31, 2025Total Liabilities
7.27MUSDFY2025 · Dec 31, 2025Total Non-current Assets
61.90MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
285.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
6.98MUSDFY2025 · Dec 31, 2025Cash Equivalents
35.69MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
35.69MUSDFY2025 · Dec 31, 2025Other Short-term Investments
65.39MUSDFY2025 · Dec 31, 2025Accounts Payable
2.27MUSDFY2025 · Dec 31, 2025Short-term Debt
256.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
59.00KUSDFY2025 · Dec 31, 2025Long-term Debt
285.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-289.73MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
160.47MUSDvs all stocks (USD)
52-Week Low
1.36USDUpdated Jul 18, 202652-Week High
14.41USDUpdated Jul 18, 202652-Week Change
800.74%vs all stocks
Beta
0.0750xvs all stocks
50-Day MA
11.78USDUpdated Jul 18, 2026200-Day MA
6.43USDUpdated Jul 18, 2026Avg 10-Day Volume
1.38MSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.53MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.7700USDUpdated Jul 18, 2026Other Income / Expense
-291.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 27.86×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 27.86Industry median: 5.64Industry P95: 23.02Peers compared: 261
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Getein Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRule
Senores Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
SS Innovations International, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Immix Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Biolight Meditech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aura Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Teyi Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shattuck Labs Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Yabao Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oculis Holding AG
Tier 1ProductionApproval-Gated PipelineRule